Amygdala Neurosciences, Inc. is a biopharmaceutical company based in San Francisco, CA, dedicated to developing innovative medicines for the treatment of substance use disorders (SUD). With a focus on inventing and advancing first-in-class drugs, their mission is to provide effective solutions for individuals struggling with addiction.
Leading the way in the discovery and development of ALDH2 inhibitors, Amygdala Neurosciences aims to help patients overcome cravings associated with substance misuse. By addressing the science of addiction, they strive to offer new therapeutic options that can alleviate compulsive drug-seeking behavior and improve the lives of those affected by SUD.
Generated from the website